Company research
RETRACTABLE TECHNOLOGIES INC
CIK 946563Updated Sep 27, 2026
SecurityRVP · NYSE_AMERICAN · equity
RVP price & chart
Loading TradingView…
AMEX:RVP on TradingView ↗About the company
Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint® needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general line distributors.
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01, 9.01
10-Q filing
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
10-Q filing
Show 5 more recent filings
Submission of Matters to a Vote of Security Holders
Items 5.07
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
10-K filing
DEFA14A filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 142,630,289Source | 160,724,202Source | 179,672,212Source | 195,665,665Source |
| Property, Plant and Equipment, NetUSD | 79,180,049Source | 87,348,518Source | 93,478,521Source | 100,152,768Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,588,625Source | 4,235,388Source | 12,667,550Source | 19,721,345Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 7,904,120Source | 7,786,697Source | 10,671,721Source | 4,835,119Source |
| Inventory, NetUSD | 17,188,397Source | 19,189,753Source | 17,581,368Source | 20,684,168Source |
| Assets, CurrentUSD | 63,083,330Source | 73,272,059Source | 77,649,597Source | 88,809,710Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 68,255,272Source | 73,553,511Source | 80,384,553Source | 89,128,856Source |
| Stockholders’ equity: | ||||
| Retained Earnings (Accumulated Deficit)USD | 13,872,917Source | 26,668,591Source | 38,785,559Source | 46,028,541Source |
| Stockholders' Equity Attributable to ParentUSD | 74,375,017Source | 87,170,691Source | 99,287,659Source | 106,536,809Source |
| Liabilities and EquityUSD | 142,630,289Source | 160,724,202Source | 179,672,212Source | 195,665,665Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 9,597,692Source | 8,780,916Source | 9,377,496Source | 12,135,822Source |
| Accounts Payable, CurrentUSD | 5,339,797Source | 4,290,588Source | 4,779,035Source | 6,404,925Source |
| Other Liabilities, NoncurrentUSD | 58,127,212Source | 63,872,553Source | 69,773,538Source | 75,459,612Source |
| Additional Financial Items | ||||
| Dividends Payable, CurrentUSD | 1,417,438Source | 1,417,437Source | 1,417,437Source | 1,417,937Source |
| Long-term DebtUSD | 895,645Source | — | — | — |
| Long-term Debt, Current MaturitiesUSD | — | 332,480Source | 303,991Source | 285,954Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 900,042Source | 1,233,519Source | 1,533,422Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -12,565,230Source | -11,886,524Source | -7,011,036Source | 5,078,557Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 7,765,990Source | 7,569,946Source | 7,527,227Source | 4,602,961Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 451,154Source | -2,313,342Source | 6,463,542Source | -29,701,396Source |
| Increase (Decrease) in InventoriesUSD | 197,474Source | 1,608,385Source | -2,927,445Source | 94,249Source |
| Increase (Decrease) in Accounts PayableUSD | 1,049,209Source | -488,447Source | -1,625,890Source | -13,999,647Source |
| Deferred Income Tax Expense (Benefit)USD | — | 8,392,031Source | -1,873,366Source | 7,347,172Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -7,064,378Source | -11,557,036Source | 2,766,848Source | 16,768,128Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 5,984,936Source | 3,660,307Source | -10,762,283Source | -31,202,814Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 1,439,943Source | 852,979Source | 16,830,077Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | — | 7,618,177Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -567,321Source | -535,433Source | 941,640Source | 4,993,118Source |
| Repayments of Long-term DebtUSD | 336,877Source | 304,988Source | 281,866Source | 283,933Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -1,646,763Source | -8,432,162Source | -7,053,795Source | -9,441,568Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 2,588,625Source | 4,235,388Source | 12,667,550Source | 19,721,345Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 87,904Source | 122,500Source | 161,322Source | 110,537Source |
| Income Taxes Paid, NetUSD | -346,907Source | — | -9,747,329Source | — |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | — | 9,157Source | 60,115Source |
| Share-based Payment Arrangement, ExpenseUSD | — | 0Source | 0Source | — |
| Debt and Equity Securities, Realized Gain (Loss)USD | 5,626,262Source | — | — | — |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | -5,035,991Source | 10,806,320Source | -10,521,166Source | 2,343,359Source |
| DepreciationUSD | 7,800,000Source | 7,600,000Source | 7,527,227Source | 4,602,961Source |
| Dividends Payable, CurrentUSD | 1,417,438Source | 1,417,437Source | 1,417,437Source | 1,417,937Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | 5,626,262Source | — | 5,574,792Source | -327,926Source |
| Gain (Loss) Related to Litigation SettlementUSD | 1,900,000Source | — | — | — |
| General and Administrative ExpenseUSD | 12,772,469Source | 13,555,283Source | 14,308,365Source | 24,036,480Source |
| Income Tax Expense (Benefit)USD | 291,293Source | 8,366,190Source | -1,905,161Source | 83,870Source |
| InterestExpenseNonoperatingUSD | 87,904Source | 122,500Source | — | — |
| Inventory Write-downUSD | 2,198,831Source | — | 175,355Source | — |
| Net Income (Loss) Attributable to ParentUSD | -12,565,230Source | -11,886,524Source | -7,011,036Source | 5,078,557Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -12,795,674Source | -12,116,968Source | -7,242,982Source | 4,846,113Source |
| Operating ExpensesUSD | 21,222,227Source | 20,077,391Source | 20,596,020Source | 29,106,259Source |
| Payments to Acquire InvestmentsUSD | 30,535,868Source | 899,750Source | 68,481,490Source | 18,135,191Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 13,800Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | — | 10,100,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 38,266,211Source | 33,049,533Source | 43,596,926Source | 94,818,938Source |
| Cost of RevenueUSD | 38,219,165Source | 34,077,709Source | 34,489,115Source | 66,565,655Source |
| Operating Income (Loss)USD | -21,175,181Source | -21,105,567Source | -11,488,209Source | -852,976Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -12,273,937Source | -3,520,334Source | -8,916,197Source | 5,162,427Source |
| Income Tax Expense (Benefit)USD | 291,293Source | 8,366,190Source | -1,905,161Source | 83,870Source |
| Net Income (Loss) Attributable to ParentUSD | -12,565,230Source | -11,886,524Source | -7,011,036Source | 5,078,557Source |
| Earnings Per Share, BasicUSD per share | -0.43Source | -0.4Source | -0.24Source | 0.15Source |
| Earnings Per Share, DilutedUSD per share | -0.43Source | -0.4Source | -0.24Source | 0.15Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 29,937,159Source | 29,937,159Source | 29,937,159Source | 32,896,348Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 29,937,159Source | 29,937,159Source | 29,937,159Source | 32,961,945Source |
| Interest Expense (non-operating)USD | 87,904Source | 122,500Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 291,293Source | -25,841Source | -31,795Source | -7,263,302Source |
| Debt and Equity Securities, Realized Gain (Loss)USD | 5,626,262Source | — | — | — |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | -5,035,991Source | 10,806,320Source | -10,521,166Source | 2,343,359Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | 5,626,262Source | — | 5,574,792Source | -327,926Source |
| Gain (Loss) Related to Litigation SettlementUSD | 1,900,000Source | — | — | — |
| General and Administrative ExpenseUSD | 12,772,469Source | 13,555,283Source | 14,308,365Source | 24,036,480Source |
| Gross ProfitUSD | 47,046Source | -1,028,176Source | 9,107,811Source | 28,253,283Source |
| Interest ExpenseUSD | — | — | 152,166Source | 170,651Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -12,795,674Source | -12,116,968Source | -7,242,982Source | 4,846,113Source |
| Operating ExpensesUSD | 21,222,227Source | 20,077,391Source | 20,596,020Source | 29,106,259Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | 230,444Source | 230,444Source | 231,946Source | 232,444Source |
| Research and Development ExpenseUSD | 675,567Source | 673,944Source | 581,172Source | 525,727Source |
| Selling and Marketing ExpenseUSD | 6,819,825Source | 5,848,164Source | 5,706,483Source | 4,544,052Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | — | 10,100,000Source |
Filing attachments
tm269857d1_ex99-1.htm · 8-K · 2026-03-27
EX-99.1 2 tm269857d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 RETRACTABLE TECHNOLOGIES, INC. REPORTS RESULTS FOR 2025 LITTLE ELM, Texas, March 27, 2026 - Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2025. Further details concerning the results of operations as well as other matters are available in Retractable’s Form 10-K filed on March 27, 2026 with the U.S. Securities and Exchange Commission. The Company’s reve…
Read attachment ↗tm269857d1_ex99-2.htm · 8-K · 2026-03-27
EX-99.2 3 tm269857d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 RETRACTABLE TECHNOLOGIES, INC. DECLARES DIVIDENDS TO SERIES II AND III CLASS B PREFERRED STOCK SHAREHOLDERS LITTLE ELM, Texas, March 27, 2026 - Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively. Dividends …
Read attachment ↗tm2531255d1_ex99-1.htm · 8-K · 2025-11-14
EX-99.1 2 tm2531255d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 RETRACTABLE TECHNOLOGIES, INC. RESULTS FOR THE PERIODS ENDED SEPTEMBER 30, 2025 LITTLE ELM, TEXAS, November 14, 2025 - Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $10.1 million for the third quarter of 2025 and an operating loss of $3.7 million for the period, as compared to total net sales for the same period last year of $10.3 million and an operating loss of $5.1 million. For the first nine mo…
Read attachment ↗tm2531255d1_ex99-2.htm · 8-K · 2025-11-14
EX-99.2 3 tm2531255d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Retractable Technologies, Inc. Receives Innovative Technology Designation from Vizient for EasyPoint Blood Collection Tube Holder with Needle LITTLE ELM, TEXAS, November 14, 2025 - Retractable Technologies, Inc. (NYSE American: RVP) announces its EasyPoint® Blood Collection Tube Holder with Needle has received an Innovative Technology designation from Vizient®, the largest healthcare performance improvement company in the country.…
Read attachment ↗tm2510750d1_ex99-1.htm · 8-K · 2025-03-28
EX-99.1 2 tm2510750d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 RETRACTABLE TECHNOLOGIES, INC. REPORTS RESULTS FOR 2024 LITTLE ELM, Texas, March 28, 2025 - Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2024. Further details concerning the results of operations as well as other matters are available in Retractable’s Form 10-K filed on March 28, 2025 with the U.S. Securities and Exchange Commission. The Company’s rev…
Read attachment ↗tm2510750d1_ex99-2.htm · 8-K · 2025-03-28
EX-99.2 3 tm2510750d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 RETRACTABLE TECHNOLOGIES, INC. DECLARES DIVIDENDS TO SERIES II AND III CLASS B PREFERRED STOCK SHAREHOLDERS LITTLE ELM, Texas, March 28, 2025 - Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively. Dividends…
Read attachment ↗